Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06338332

Obstructive Colon Cancer, a Bridge to Surgery in Right Sided Obstructive Colon Cancer

Rationale: Approximately 13% (range 10-28%) of all colorectal cancer patients (CRC) present with an acute obstruction. Postoperative mortality after an emergency resection is known for its high risk of morbidity and mortality. Different options can be considered in the management of obstructing right sided CRC: 1) primary resection, simultaneous treatment of obstruction and tumour resection, or 2) staged treatment of the obstruction with secondary resection of the tumour. Currently, in the Netherlands, an emergency resection has been judged to be inferior to postponing surgery. Patients who present with right sided obstructive colon cancer at one of the participating hospitals are subjected to a bridge to surgery (BTS) protocol.

Objective: The primary objective of this study is to determine the feasibility of BTS protocols in right sided obstructive colon cancer and reduce mortality- and morbidity (stoma rates, major- and minor complications) rates in potentially curable patients presenting with acute obstructing colon cancer.

Study design: This is a multicentre, prospective registration study Study population: All patients presenting with high clinical suspicion or histologically proven right sided colon cancer and signs of obstruction of the large bowel.

Intervention: Prospective registration of the implementation of bridge to surgery protocols in patients with (acute) malignant right sided obstruction of the colon, without suspicion of perforation (tumour perforation or blow out) in order to optimize patients preoperatively. The BTS approach encompasses the utilization of either ileostomy creation, stent placement or nasogastric tube for decompression, which is subsequently followed by definitive surgical treatment at a later stage. BTS also involves pre-optimization, prior to the surgical procedure, with the following approach: optimizing the nutritional health status improving the physical health status of the patient.

Main study parameters/endpoints: The primary endpoint is complication-free survival (CFS) at 90 days after hospitalization. Complication is defined here as mortality and/or development of a major complication (Clavien-Dindo classification ≥3). With a total follow up of three years. Secondary endpoints: overall mortality, morbidity (stoma rates, minor complications), in hospital stay, oncologic quality of resection and other occurring adverse events.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Amphia Hospital

Breda, North Brabant, 4818CK, Netherlands

Location status: Recruiting

Location contact

Elze Lockhorst, Drs.

CONTACT

[email protected]

+31 613723827

Jennifer Schreinemakers, MD, PhD

PRINCIPAL_INVESTIGATOR

About this study

Approximately 13% (range 8-28%) presents with acute obstructing colorectal cancer (CRC). It's known that patients with acute obstructing CRC have increased mortality and morbidity compared to patients without acute obstructing CRC. Postoperative mortality ranges from 12 to 30%, which can raise to 41% in elderly patients with two or more additional risk factors. Morbidity rates until 78% are described in older patients undergoing emergency resection for obstructing CRC.

Different treatment options have been evaluated over the years. The two main options are; 1) emergency resection, simultaneous treatment of obstruction and tumour resection, 2) staged treatment of the obstruction with secondary resection of the tumour. Postoperative mortality after an emergency resection is known for its high risk of morbidity and mortality. From the Dutch audits it is know that the risk is high, not only for left sided obstruction, but also for right sided obstruction. Until recently, an acute emergency resection was the standard treatment for patients presenting with a small bowl ileus caused by a right sided colon cancer. However, more evidence has emerged that postponing surgery with a bridge tot surgery protocol can be beneficial to the patients. The bridge to surgery approach encompasses the utilization of either ileostomy creation or stent placement for colonic decompression, which is subsequently followed by definitive surgical treatment at a later stage. Alternatively, BTS may involve the introduction of a pause, also known as preoptimization, prior to the surgical procedure. The three main options for staged surgery all have its own up- and downsides. All forms of staged treatment appears to lead to fewer morbidity and mortality.

Emergency surgery Emergency resection is associated with a high risk of mortality and morbidity. Besides that, stoma creations after emergency surgery are higher than in patients treated electively. In case of a Hartmann's procedure, (resection of a left-sided tumour and creation of a colostomy) second surgical procedure is needed to restore continuity. Continuity restore has a mean mortality of 1% (range 0-7.4%) and morbidity of 16% (range 3-50%). Alternatively, emergency resection with primary anastomosis, which has the advantage to be a definite procedure, is performed. However, this treatment can be complicated with anastomotic leakage (AL). Anastomotic leakage is higher in patients treated for obstructing CRC in comparison with staged or electively treatment. Besides that, mortality rates after anastomotic leakage after colorectal surgery varies between 5-19%. Therefore, this intervention does not align with existing treatment strategies.

Bridge to surgery Stoma creation for colonic decompression followed by definite surgical treatment in a later stadium for patients with obstructing right sided CRC is an alternative. Postoperative mortality between patients treated with emergency resection, stent or stoma followed by resection showed no differences. However, high mortality rates in elderly patients (30%) after acute resection, stress the need for alternative strategies. For right-sided colon cancer, postoperative complications for patients treated with decompressing stoma before resection are lower in comparison with acute resection. However, the creation of an ileostomy leads to a longer hospital stay. Secondly, stenting as a bridge to surgery (BTS) creates time before definite surgical treatment. However, the use of stents as a bridge to surgery has controversial results. Stents as a BTS is associated with complications like perforation, stent migration, higher recurrence rate and re-obstruction. Furthermore, three prospective trials are closed prematurely because of high morbidity rates or a high number of technical failure of the self-expandable metallic stent (SEMS) However, several studies and one meta-analysis show promising short-term outcomes for the use of stents as BTS. Besides that, promising long-term outcomes, such as oncological safety, after stents as BTS are shown. Finally, transtumoral intubation for decompression of the colon, before initial can be considered to prevent stoma creation. Thirdly, a bridge to surgery may involve the introduction of a pause, also known as preoptimization, prior the surgical procedure. This previously presented as PRE-OCC, this approach appears feasible and safe. Deteriorating physical condition caused by poor intake, vomiting, changes in electrolyte status and weight loss often results in a decreased nutritional status. Nutritional status and thereby the patients preoperative health status seems to influence the mortality risk for patients with (obstructing) colorectal cancer. Creating a pause, before surgery provides a chance to optimise the patients' medical condition, perform a complete pre-operative screening of the patient's health status and examine possible concomitant illnesses. Besides nutritional status, also the functional capacity of the patient seems to be an important factor in postoperative mortality and morbidity. Studies, in elective colorectal surgery, show promising results after improving the functional capacity of patients (prehabilitation) on the recovery after colorectal surgery. However, this third option of bridge to surgery also has some disadvantages. Preoptimization leads to an prolonged duration of stay prior to surgery in a semi acute setting, with a central venous line and potentially insufficient decompression.

This study aims to determine whether implementation of bridge to surgery protocols is feasible and reduces mortality- and morbidity (stoma rates, major- and minor complications) rates in potentially curable patients presenting with acute obstructing CRC. By prospectively collecting the data, the feasibility of the protocols will be reported and the decrease in mortality and morbidity rates can be evaluated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients age is 18 years or older
  • Patients presenting with symptoms of obstruction (including cecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon) caused by (high suspicion or histologically proven) colonic cancer.
  • Patient presenting with symptoms of partial obstruction (abdominal pain, nausea, vomiting, diarrhoea) confirmed by the presence of a dilated colon or ileum with a computed tomography (CT-scan).
  • Treatment with curative intent.

Exclusion criteria

  • Obstruction of the colon pathologically caused by benign disease.
  • Obstruction of the colon caused by an extra-colonic malignancy.
  • Suspicion of emergency complications caused by peritonitis due to perforation (tumour or blow out) or sepsis.
  • Patients with advanced disease who will undergo a palliative trajectory.
  • Rectal cancer

Treatment and study plan

Primary outcomes

  1. Complication-free survival

    Time frame: 90 days after hospitalization

    The primary endpoint is complication-free survival (CFS) at 90 days after hospitalization. Complication is defined here as mortality and/or development of a major complication (Clavien-Dindo classification ≥3).

Secondary outcomes

  1. Complications overall

    Time frame: 90 days after hospitalization

    All complications (following Clavien-Dindo classification) within 90 days after hospitalisation

  2. Type of surgical intervention

    Time frame: Day of surgery

    Type of surgical intervention

  3. Time till surgery

    Time frame: Days from admission untill day of surgery (up to 100 days)

    Days from admission untill day of surgery

  4. Resection

    Time frame: Day of the surgery

    Creation of primary anastomosis or stoma creation

  5. TNM

    Time frame: Day of the surgery

    Cancer stage (clinical and pathological) according to the tumour node metastasis (TNM) classification of the American Joint Committee

  6. Hospital stay

    Time frame: Days between surgery and moment of discharge (up to 100 days)

    Total hospital stay (in total, after resection or reoperation) (days)

  7. One year stoma rate

    Time frame: One year postoperative

    One year stoma rate, patients with a stoma after one year

  8. One year survival rates

    Time frame: One years postoperative

    One year survival rates

  9. Disease free survival rates one year

    Time frame: One years postoperative

    Rate of patients with disease free survical one year postoperative based on radiological assessment

  10. Disease free survival rates three years

    Time frame: Three years postoperative

    Rate of patients with disease free survical three year postoperative based on radiological assessment

  11. Three year survival rates

    Time frame: Three years postoperative

    Three year survival rates

  12. Tumour type (obstructing, not obstructing),

    Time frame: At time of diagnosis

    Was there an obstructive tumor?

  13. Metastasis preoperative

    Time frame: At time of diagnosis

    Presence of metastases at the time of diagnosis

  14. Pre-operative diagnostics

    Time frame: At time of diagnosis

    Endoscopy, CT-scan, ultrasound and/or MRI

  15. Type of bridge-to-surgery

    Time frame: At time of diagnosis

    Ileostomy, stent or nasogastric tube for decompression

  16. Nutrition (TPN/extra nutrition)

    Time frame: During hospital stay (up to 100 days)

    Did the patient received additional nutrition?

  17. Consultation of other specialist

    Time frame: During hospital stay (up to 100 days)

    Consultation of other specialist during hospital stay

Other outcomes

  1. Gender

    Time frame: At time of diagnosis

    male/female

  2. Age at surgery

    Time frame: At time of diagnosis

    Age at surgery (years, min 18years-max 120 years)

  3. ASA

    Time frame: At time of diagnosis

    American Society of Anaesthesiologists (ASA) score (I-V)

  4. Bodyweight

    Time frame: At time of diagnosis

    Bodyweight at hospital presentation (kilograms, min 30 - max 150)

  5. Height

    Time frame: At time of diagnosis

    Height (centimeters, min 120cm - max 230cm)

  6. Concomitant and previous therapy

    Time frame: At time of diagnosis

    Concomitant and previous therapy for this tumour (chemotherapy/radiation)

  7. C-reactive protein

    Time frame: During hospital stay (up to 1 week postoperative)

    C-reactive protein (CRP, mg/L) (0-500, higher score is worse)

  8. Haemoglobin

    Time frame: During hospital stay (up to 1 week postoperative)

    Haemoglobin (Hb, g/dL) (1-12, lower score is worse)

  9. Laboratory values

    Time frame: During hospital stay (up to 1 week postoperative)

    Hematocrit (H, %) (0-100, the normal hematocrit for men is 40 to 54%; for women it is 36 to 48%)

  10. Leukocytes

    Time frame: During hospital stay (up to 1 week postoperative)

    Leukocytes (× 10^9/L), the normal range is 4.5 to 11.0 × 109/L

  11. Prothrombin time

    Time frame: During hospital stay (up to 1 week postoperative)

    Prothrombin time (PTT, seconds), normal range is 11 to 13.5 seconds

  12. Sodium

    Time frame: During hospital stay (up to 1 week postoperative)

    Sodium (mEq/L), normal range 135 to 145 milliequivalents per liter (mEq/L)

  13. Potassium

    Time frame: During hospital stay (up to 1 week postoperative)

    Potassium (mmol/L), normal range 3.6 to 5.2 millimoles per liter

  14. Glomerular filtration rate

    Time frame: During hospital stay (up to 1 week postoperative)

    Glomerular filtration rate (GFR, mL/min/1.73 m2), normal value >90

  15. Albumin

    Time frame: During hospital stay (up to 1 week postoperative)

    Albumin (g/dL), normal range 3.5 to 5.5 grams per deciliter

  16. Bilirubin

    Time frame: During hospital stay (up to 1 week postoperative)

    Bilirubin (µmol/L), normal value less than 5.1 µmol/L

  17. ASAT

    Time frame: During hospital stay (up to 1 week postoperative)

    Alanine- Amino-Transferase (ASAT, U/L), normal range 8 to 33 U/L

  18. ALAT

    Time frame: During hospital stay (up to 1 week postoperative)

    Aspartate-Amino -transferase (ALAT, U/L), normal range 4 to 36 U/L

  19. LDH

    Time frame: During hospital stay (up to 1 week postoperative)

    Lactic acid dehydrogenase (LDH,U/L), normal range 140 to 280 U/L

  20. ALP

    Time frame: During hospital stay (up to 1 week postoperative)

    Alkaline phosphatase (ALP, IU/L), normal range 44 to 147

  21. Gamma-GT

    Time frame: During hospital stay (up to 1 week postoperative)

    Gamma-GT (U/L), normal range 0 to 30 IU/L

  22. Creatinkinase

    Time frame: During hospital stay (up to 1 week postoperative)

    Creatinkinase (U/L), norman range 22 to 198

  23. Phosphate

    Time frame: During hospital stay (up to 1 week postoperative)

    Phosphate (mg/dL), normal range 2.5 to 4.5

  24. Lactate

    Time frame: During hospital stay (up to 1 week postoperative)

    Lactate (mg/dL), normal value <1.0

Study contacts

Contact information is provided by the study sponsor or research team.

Elze Lockhorst, Drs.

CONTACT

[email protected]

+31613723827

Sponsors and collaborators

Lead sponsor

Amphia Hospital

Other

Registry information

Acronym: OCCBRIGHT

Important dates

Study start
2024
Primary completion
2025
Study completion
2028
First posted
Mar 29, 2024
Registry last updated
Mar 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.